Hospital
ST Dominic-Jackson Memorial Hospital
ST Dominic-Jackson Memorial Hospital was paid $37.09M by Medicaid between Jan 2018 and Dec 2024, across 446 billing codes. Its largest line is 99284, emergency room visit (serious) — 11% of everything it billed.
33Billing provider infoST DOMINIC-JACKSON MEMORIAL HOSPITAL
JACKSON, MS 39216
JACKSON, MS 39216
33aNPI1306876065assigned 07/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$37.09M
24GClaims1,607,519
24DCodes billed446
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#13 of 77
Median peer was paid$8.23M
This provider vs. median4.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 219,224 | $5.57M | |
| 2019 | 246,423 | $6.01M | |
| 2020 | 200,920 | $5.07M | |
| 2021 | 221,609 | $5.89M | |
| 2022 | 298,676 | $4.77M | |
| 2023 | 247,812 | $5.53M | |
| 2024incomplete | 172,855 | $4.26M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 29,460 | 21,728 | $3.91M |
| G0378 | Hospital observation service, per hour | 10% | 16,190 | 11,791 | $3.72M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.0% | 21,604 | 16,386 | $3.34M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.3% | 20,448 | 15,026 | $1.96M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.6% | 12,282 | 5,825 | $1.32M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.3% | 18,976 | 13,621 | $1.22M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.9% | 15,303 | 10,259 | $1.06M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 7,866 | 6,396 | $885K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 27,853 | 20,296 | $710K |
| J9271 | Injection, pembrolizumab, 1 mg | 1.9% | 961 | 312 | $698K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 43,141 | 28,232 | $604K |
| J2505 | Injection, pegfilgrastim, 6 mg | 1.5% | 532 | 351 | $573K |
434 more codes
| 86900 | 1.4% | 12,918 | $534K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.3% | 1,638 | $494K |
| 86885 | 1.3% | 7,391 | $467K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 18,588 | $459K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 9,381 | $451K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 12,926 | $426K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.1% | 4,210 | $423K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 21,453 | $421K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 97,320 | $405K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 8,916 | $398K |
| 77412 | 1.1% | 8,473 | $397K | |
| 83880 | <1% | 17,801 | $329K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,828 | $329K |
| 93458 | <1% | 473 | $323K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,573 | $311K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 56,578 | $294K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 4,222 | $294K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,498 | $282K |
| 80053 | Comprehensive metabolic panel | <1% | 54,774 | $257K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,669 | $250K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 15,939 | $244K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,438 | $237K |
| 78431 | <1% | 273 | $211K | |
| 78492 | <1% | 557 | $206K | |
| 84484 | <1% | 33,625 | $206K | |
| J0897 | Injection, denosumab, 1 mg | <1% | 592 | $205K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 3,643 | $198K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,043 | $191K |
| 80076 | <1% | 31,121 | $171K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,550 | $166K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,644 | $165K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 2,506 | $164K |
| 86901 | <1% | 12,912 | $163K | |
| 93970 | <1% | 2,463 | $155K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,998 | $153K |
| 88307 | <1% | 1,653 | $153K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 96,608 | $149K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 4,610 | $148K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,571 | $145K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 2,682 | $136K |
| 93454 | <1% | 211 | $128K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 13,895 | $125K |
| 72100 | <1% | 2,987 | $125K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,664 | $114K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,477 | $110K |
| 76801 | <1% | 1,883 | $109K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,597 | $107K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,678 | $105K |
| 96415 | <1% | 2,935 | $104K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,347 | $104K |
| 93971 | <1% | 3,171 | $98K | |
| 58571 | <1% | 60 | $98K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,651 | $96K |
| 59025 | Fetal non-stress test | <1% | 977 | $95K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,731 | $91K |
| 70496 | <1% | 1,304 | $86K | |
| 47562 | <1% | 53 | $86K | |
| 86850 | <1% | 5,041 | $84K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,899 | $83K |
| 85730 | <1% | 26,194 | $82K | |
| 29581 | <1% | 1,989 | $81K | |
| 81025 | <1% | 16,809 | $81K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,173 | $79K |
| 85610 | <1% | 35,893 | $77K | |
| 74018 | <1% | 2,699 | $77K | |
| 96417 | <1% | 3,240 | $73K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,034 | $69K |
| 93017 | <1% | 974 | $69K | |
| 80061 | Lipid panel | <1% | 8,697 | $67K |
| J9299 | Injection, nivolumab, 1 mg | <1% | 500 | $66K |
| 71250 | <1% | 2,358 | $63K | |
| 36902 | <1% | 73 | $62K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,066 | $57K |
| 77300 | <1% | 553 | $57K | |
| 77336 | <1% | 1,649 | $56K | |
| 72141 | <1% | 773 | $56K | |
| 77334 | <1% | 248 | $55K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 983 | $53K |
| 73560 | <1% | 1,960 | $52K | |
| 64450 | <1% | 913 | $51K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 361 | $51K |
| 83690 | <1% | 13,766 | $51K | |
| 80074 | <1% | 1,894 | $51K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,009 | $50K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,932 | $49K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,917 | $48K |
| 36430 | <1% | 627 | $47K | |
| 88304 | <1% | 2,007 | $47K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,455 | $46K |
| 93979 | <1% | 2,026 | $46K | |
| 77295 | <1% | 123 | $45K | |
| 82805 | <1% | 1,196 | $43K | |
| 97162 | <1% | 1,872 | $43K | |
| 81003 | <1% | 32,489 | $43K | |
| 97163 | <1% | 2,068 | $42K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 8,636 | $42K |
| 84702 | <1% | 4,439 | $40K | |
| 93978 | <1% | 888 | $40K | |
| 96367 | <1% | 1,668 | $40K | |
| 86923 | <1% | 1,044 | $39K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 2,311 | $39K |
| 73030 | <1% | 1,427 | $38K | |
| 87400 | <1% | 2,403 | $38K | |
| 76770 | <1% | 1,028 | $36K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,241 | $35K |
| 83735 | <1% | 11,854 | $34K | |
| 70498 | <1% | 880 | $33K | |
| 86780 | <1% | 3,634 | $33K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,376 | $30K |
| 87186 | <1% | 5,390 | $28K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 438 | $28K |
| 37238 | <1% | 16 | $28K | |
| 82565 | <1% | 9,141 | $28K | |
| 85027 | <1% | 13,306 | $27K | |
| 88342 | <1% | 644 | $26K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 230 | $25K |
| 73630 | <1% | 891 | $25K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,605 | $24K |
| 76000 | <1% | 558 | $24K | |
| 82607 | <1% | 2,719 | $24K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 691 | $24K |
| 74019 | <1% | 552 | $23K | |
| 72040 | <1% | 749 | $23K | |
| 87040 | <1% | 3,978 | $23K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,330 | $22K |
| 87070 | <1% | 4,497 | $21K | |
| 76642 | <1% | 590 | $21K | |
| 97113 | <1% | 503 | $20K | |
| 78195 | <1% | 130 | $20K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 192 | $20K |
| 72131 | <1% | 599 | $20K | |
| 83605 | <1% | 4,322 | $19K | |
| 97167 | <1% | 1,130 | $19K | |
| 77290 | <1% | 173 | $18K | |
| 86140 | <1% | 6,457 | $18K | |
| 97750 | <1% | 1,919 | $18K | |
| 84703 | <1% | 3,995 | $18K | |
| 81001 | <1% | 13,624 | $18K | |
| 87077 | <1% | 3,471 | $17K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 116 | $17K |
| 88720 | <1% | 4,086 | $17K | |
| 96402 | <1% | 867 | $17K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,429 | $16K |
| 82077 | <1% | 1,974 | $16K | |
| 82728 | <1% | 2,203 | $15K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 443 | $15K |
| 88112 | <1% | 684 | $15K | |
| 97166 | <1% | 686 | $14K | |
| 36569 | <1% | 52 | $13K | |
| 84146 | <1% | 1,523 | $12K | |
| 97161 | <1% | 609 | $12K | |
| 97116 | <1% | 2,933 | $12K | |
| 85007 | <1% | 9,930 | $12K | |
| 87430 | <1% | 1,296 | $12K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 145 | $11K |
| 86038 | <1% | 1,195 | $10K | |
| 82962 | <1% | 18,328 | $10K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,449 | $10K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 511 | $10K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 467 | $10K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,554 | $10K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 144 | $9K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 343 | $9K |
| 97165 | <1% | 470 | $9K | |
| 74178 | <1% | 105 | $9K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $8K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 171 | $8K |
| 82746 | <1% | 1,104 | $8K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,220 | $8K |
| 73501 | <1% | 263 | $8K | |
| 84439 | <1% | 1,427 | $8K | |
| 36600 | <1% | 398 | $8K | |
| 75820 | <1% | 29 | $7K | |
| 73502 | <1% | 457 | $7K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,495 | $7K |
| 77066 | Tomosynthesis, mammo | <1% | 131 | $7K |
| 93880 | <1% | 178 | $7K | |
| 78264 | <1% | 41 | $7K | |
| 84550 | <1% | 2,665 | $7K | |
| J2997 | Injection, alteplase recombinant, 1 mg | <1% | 111 | $7K |
| 85045 | <1% | 2,759 | $7K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 25,612 | $7K |
| 84100 | <1% | 3,964 | $7K | |
| 87147 | <1% | 1,909 | $7K | |
| 77065 | Tomosynthesis, mammo | <1% | 201 | $6K |
| 85651 | <1% | 2,652 | $6K | |
| 70486 | <1% | 163 | $6K | |
| 85014 | <1% | 5,207 | $6K | |
| 83615 | <1% | 1,667 | $6K | |
| 82550 | <1% | 2,372 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,875 | $6K |
| 85652 | <1% | 4,232 | $6K | |
| 82247 | <1% | 1,896 | $6K | |
| L8000 | Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type | <1% | 118 | $6K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,309 | $6K |
| 84460 | <1% | 1,370 | $6K | |
| 84450 | <1% | 1,360 | $6K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 14,843 | $6K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 35 | $5K |
| 97014 | <1% | 854 | $5K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 29 | $5K |
| 82150 | <1% | 1,501 | $5K | |
| 82948 | <1% | 1,497 | $5K | |
| 73610 | <1% | 157 | $5K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 690 | $5K |
| 73130 | <1% | 196 | $5K | |
| 96411 | <1% | 168 | $5K | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 16 | $5K |
| 77280 | <1% | 121 | $4K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 341 | $4K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 46 | $4K |
| 73221 | <1% | 43 | $4K | |
| 87205 | <1% | 2,039 | $4K | |
| 70491 | <1% | 38 | $4K | |
| 86431 | <1% | 934 | $4K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 180 | $4K |
| 83540 | <1% | 1,061 | $4K | |
| 88300 | <1% | 251 | $4K | |
| 86592 | <1% | 1,469 | $4K | |
| 87340 | <1% | 615 | $3K | |
| 72156 | <1% | 40 | $3K | |
| 95816 | <1% | 50 | $3K | |
| 77331 | <1% | 63 | $3K | |
| 72070 | <1% | 59 | $3K | |
| 70544 | <1% | 98 | $3K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 1,651 | $3K |
| 86200 | <1% | 318 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,135 | $3K |
| 84153 | <1% | 266 | $3K | |
| 72158 | <1% | 28 | $3K | |
| 84466 | <1% | 479 | $3K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 1,057 | $3K |
| 86235 | <1% | 38 | $3K | |
| 87081 | <1% | 1,054 | $3K | |
| 92610 | <1% | 203 | $2K | |
| 85379 | <1% | 515 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 46 | $2K |
| 84156 | <1% | 869 | $2K | |
| 76937 | <1% | 2,770 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 135 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 15,490 | $2K |
| 93922 | <1% | 102 | $2K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,516 | $2K |
| 62270 | <1% | 16 | $2K | |
| 80164 | <1% | 219 | $2K | |
| 83550 | <1% | 469 | $2K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 2,622 | $2K |
| 64447 | <1% | 12 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 32 | $2K |
| 75635 | <1% | 58 | $2K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 14 | $2K |
| 87116 | <1% | 231 | $2K | |
| 93923 | <1% | 40 | $2K | |
| C1769 | Guide wire | <1% | 5,126 | $2K |
| 86696 | <1% | 109 | $2K | |
| 96376 | <1% | 15,392 | $1K | |
| 87102 | <1% | 322 | $1K | |
| 87536 | <1% | 28 | $1K | |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 835 | $1K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 2,858 | $1K |
| 73562 | <1% | 42 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 149 | $1K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,779 | $1K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 455 | $1K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,181 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 13,051 | $1K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 4,691 | $1K |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 22 | $1K |
| 85018 | <1% | 2,149 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 10,373 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 15,411 | $1K |
| 74174 | <1% | 15 | $1K | |
| 80069 | <1% | 721 | $981.68 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 17,326 | $955.79 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,477 | $888.82 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 3,349 | $863.27 |
| 87075 | <1% | 148 | $860.59 | |
| 87206 | <1% | 231 | $825.96 | |
| 87210 | <1% | 430 | $821.95 | |
| 90937 | <1% | 40 | $763.58 | |
| 82570 | <1% | 180 | $761.32 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,659 | $753.23 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 923 | $748.28 |
| 86706 | <1% | 473 | $627.50 | |
| 87899 | <1% | 71 | $624.03 | |
| 73110 | <1% | 12 | $559.94 | |
| 84481 | <1% | 62 | $541.38 | |
| 82784 | <1% | 51 | $528.05 | |
| 86360 | <1% | 16 | $522.10 | |
| 96377 | <1% | 213 | $447.41 | |
| 86304 | <1% | 31 | $446.52 | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 137 | $430.50 |
| 89050 | <1% | 151 | $429.65 | |
| 86359 | <1% | 16 | $419.20 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 33 | $418.47 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 9,657 | $401.96 |
| 82375 | <1% | 185 | $392.80 | |
| C1753 | Catheter, intravascular ultrasound | <1% | 201 | $391.32 |
| 82272 | <1% | 139 | $390.38 | |
| 72020 | <1% | 16 | $389.91 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 1,903 | $376.14 |
| 37252 | <1% | 46 | $312.69 | |
| 85347 | <1% | 213 | $294.13 | |
| 86160 | <1% | 16 | $293.26 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 939 | $280.16 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 7,634 | $279.91 |
| 82043 | <1% | 73 | $272.91 | |
| 82945 | <1% | 101 | $237.31 | |
| 88313 | <1% | 14 | $233.01 | |
| 84157 | <1% | 101 | $232.57 | |
| 83050 | <1% | 172 | $223.24 | |
| 94770 | <1% | 18 | $221.36 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,843 | $220.08 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 315 | $217.06 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 2,070 | $214.83 |
| 84132 | <1% | 86 | $210.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,759 | $200.23 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 6,303 | $198.93 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,151 | $194.13 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,276 | $182.09 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,874 | $168.57 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 115 | $164.83 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 2,146 | $148.74 |
| 82009 | <1% | 48 | $146.52 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 16 | $142.04 |
| C9399 | Unclassified drugs or biologicals | <1% | 19 | $137.49 |
| 82947 | <1% | 83 | $133.88 | |
| A6213 | Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing | <1% | 68 | $130.68 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,827 | $127.11 |
| 82800 | <1% | 20 | $108.90 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 4,584 | $106.44 |
| 86403 | <1% | 15 | $102.92 | |
| 85460 | <1% | 15 | $95.22 | |
| 87015 | <1% | 30 | $90.15 | |
| 84425 | <1% | 17 | $84.07 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 21 | $83.16 |
| 84112 | <1% | 674 | $81.58 | |
| 84520 | <1% | 13 | $63.20 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 2,078 | $58.15 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 337 | $55.48 |
| 77062 | <1% | 83 | $54.78 | |
| 82248 | <1% | 15 | $50.73 | |
| 83721 | <1% | 20 | $47.25 | |
| 77387 | <1% | 555 | $46.20 | |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | <1% | 310 | $38.58 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 110 | $37.93 |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 1,571 | $35.74 |
| 89051 | <1% | 16 | $35.28 | |
| 77061 | <1% | 14 | $25.08 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 490 | $22.57 |
| A9270 | Non-covered item or service | <1% | 7,151 | $21.39 |
| J3490 | Unclassified drugs | <1% | 289 | $19.79 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | <1% | 353 | $19.44 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 327 | $19.24 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 863 | $18.13 |
| 84202 | <1% | 12 | $18.08 | |
| 84145 | <1% | 762 | $15.90 | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 45 | $15.71 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,826 | $15.70 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 7,280 | $15.61 |
| 84590 | <1% | 12 | $14.62 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 154 | $12.79 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 306 | $12.54 |
| J0583 | Injection, bivalirudin, 1 mg | <1% | 71 | $10.91 |
| 0441U | <1% | 95 | $9.76 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,730 | $8.92 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 679 | $7.91 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 121 | $6.50 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 342 | $6.15 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 286 | $5.36 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 76 | $5.14 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 379 | $2.69 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 396 | $2.48 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 150 | $1.01 |
| 96368 | <1% | 386 | $0.69 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 983 | $0.63 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | <1% | 12 | $0.62 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 134 | $0.60 |
| J1643 | Injection, heparin sodium (pfizer), not therapeutically equivalent to j1644, per 1000 units | <1% | 109 | $0.57 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 396 | $0.43 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 54 | $0.13 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 4,066 | $0.00 |
| C1876 | Stent, non-coated/non-covered, with delivery system | 0% | 35 | $0.00 |
| 36005 | 0% | 18 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 114 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 1,615 | $0.00 |
| 99152 | 0% | 1,011 | $0.00 | |
| J0595 | Injection, butorphanol tartrate, 1 mg | 0% | 423 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 222 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 194 | $0.00 |
| 37253 | 0% | 52 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 16 | $0.00 |
| C1729 | Catheter, drainage | 0% | 90 | $0.00 |
| C1757 | Catheter, thrombectomy/embolectomy | 0% | 19 | $0.00 |
| 78434 | 0% | 273 | $0.00 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | 0% | 36 | $0.00 |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 0% | 269 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 54 | $0.00 |
| 77012 | 0% | 96 | $0.00 | |
| C1874 | Stent, coated/covered, with delivery system | 0% | 56 | $0.00 |
| C1788 | Port, indwelling (implantable) | 0% | 15 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 68 | $0.00 |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 0% | 26 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 32 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 70 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 13 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 13 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 31 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 45 | $0.00 |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | 0% | 124 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 873 | $0.00 |
| 94762 | 0% | 20 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 424 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 35 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 332 | $0.00 |
| 77001 | 0% | 227 | $0.00 | |
| 77417 | 0% | 383 | $0.00 | |
| 99153 | Mod sedat endo service >5yrs | 0% | 324 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 39 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 56 | $0.00 |
| 36410 | 0% | 100 | $0.00 | |
| Q0222 | Injection, bebtelovimab, 175 mg | 0% | 25 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 71 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 74 | $0.00 |
| G0269 | Placement of occlusive device into either a venous or arterial access site, post surgical or interventional procedure (e.g., angioseal plug, vascular plug) | 0% | 28 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 18 | $0.00 |
| Q2035 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria) | 0% | 44 | $0.00 |
| 88341 | 0% | 20 | $0.00 | |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 18 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 129 | $0.00 |
| 37239 | 0% | 23 | $0.00 | |
| C1730 | Catheter, electrophysiology, diagnostic, other than 3d mapping (19 or fewer electrodes) | 0% | 27 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 17 | $0.00 |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (flulaval) | 0% | 30 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCOTT, SAMUEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Clinch Valley Family Podiatry, PLLC | Richlands, VA | $201K |
| Sawyer Scott Eyecare Center PLLC | Sardis, MS | $110K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.